We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aegerion Admits to Violating REMS, Pushing Product to Unapproved Populations
Aegerion Admits to Violating REMS, Pushing Product to Unapproved Populations
Aegerion Pharmaceuticals pleaded guilty to two criminal misdemeanor violations of the FD&C Act, for failing to comply with REMS requirements for its Juxtapid (lomitapide) cholesterol therapy.